Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

NCT00877500 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Bilateral Breast Carcinoma
HER2/Neu Negative
Invasive Breast Carcinoma

Interventions

OTHER: Best Practice
DRUG: Ixabepilone

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]